Independent information services
Guides, comparisons, and research summaries for people working through questions around ibogaine therapy for addiction—without presenting information as a substitute for medical, legal, or clinical advice.
The work around ibogaine includes evidence, safety considerations, regulation, preparation, and longer-term recovery supports.
A working library
Open Field 11 organizes material for people affected by addiction, families, veterans, advocates, and researchers seeking careful context. For the wider framing behind this work, the ibogaine and addiction resource introduces the questions this collection is designed to hold.
Plain-language guides bring together preparation questions, safety concerns, evidence limits, and the practical work that may continue after an ibogaine experience. They are informational tools for slower, more informed reading—not directions for treatment.
Structured questions can help separate what is known, what is uncertain, and what requires qualified professional input. The aim is informed consent and careful thinking, especially where health history, medications, or legal context may matter.
Comparative material helps readers distinguish claims, settings, terminology, and research gaps without treating a comparison as a recommendation. Our approach to evidence and uncertainty explains the standards behind that distinction.
Summaries and definitions make technical language more legible while retaining the limits of the source material. For example, substance use disorder terminology has clinical meaning that should not be reduced to a single intervention or outcome measure.
How to use it
Ibogaine is a psychoactive substance associated with plants in the Apocynaceae family, and its history, terminology, and use are often discussed with more certainty than the evidence supports. The background on ibogaine is a useful starting point for terminology, but it is not a substitute for current clinical or regulatory review.
For readers considering questions specific to opioids, the independent fentanyl-focused ibogaine context can help situate a narrower concern within the broader recovery-planning conversation.
“Safety before hype means leaving room for uncertainty, questions, and the limits of what a resource can responsibly say.”
Limits are part of the service
Ibogaine has been associated with serious safety concerns, including cardiac risks and potential interactions. The U.S. Food and Drug Administration’s drug information is one authoritative place to understand why medicine-related claims and product decisions require careful, current review.
Open Field 11 does not diagnose, screen, recommend treatment, or assess whether any intervention is appropriate for an individual. It is an independent information resource focused on making complex material easier to examine with appropriate caution.
No. Open Field 11 is an independent information resource, not a clinic, medical provider, or licensed treatment center. Its materials are not medical or legal advice.
They cover guides, decision frameworks, comparisons, glossary material, research summaries, and FAQ collections related to ibogaine, safety, evidence, regulation, preparation, and longer-term recovery supports.
Because uncertainty is relevant information. Research findings, regulatory status, personal health factors, and recovery circumstances can all limit what a general resource can responsibly conclude.
Open Field 11
The purpose of these services is not to simplify a complex decision into a promise. It is to offer a clearer route through the evidence, safety considerations, language, and recovery-planning questions surrounding ibogaine.
Explore research and regulation